From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
Why It Matters
Ionis’s shift to a self‑sufficient pipeline accelerates delivery of novel RNA‑based medicines, reshaping treatment options for rare diseases and creating significant upside for investors.
Key Takeaways
- •Ionis shifted from partnered ASOs to wholly‑owned pipeline with commercialization
- •Brett Monia emphasizes perseverance despite early scientific and financial hurdles
- •Six Ionis ASO drugs approved; three more expected this year
- •Company now integrates siRNA and gene‑editing alongside antisense technologies
- •Ionis claims the strongest oligonucleotide research organization in the industry
Summary
The Business of Biotech interview with Ionis founder‑scientist Brett Monia, now CEO, explores how the RNA‑therapeutics pioneer moved from a partnership‑heavy antisense oligonucleotide (ASO) model to a wholly‑owned drug pipeline with built‑in commercialization capabilities.
Monia recounts the early scientific unknowns—cellular uptake, safety, scale‑up—and the financial strain of proving that short, chemically‑modified DNA/RNA strands could work in humans. After decades of setbacks, Ionis delivered six marketed ASO medicines and expects three additional approvals this year, while expanding into siRNA and gene‑editing platforms.
He stresses the company’s relentless focus: “If anyone is going to do this, it’s us,” and cites the spin‑out Regulus, later sold to Novartis for $1.7 billion, as proof of the platform’s value. Collaboration with Alnylam and the decision to run both antisense and siRNA programs illustrate a diversified R&D engine.
Ionis’s strategy positions it as the dominant player in oligonucleotide therapeutics, promising new treatments for rare and unmet‑need diseases and offering investors exposure to a growing, high‑margin biotech segment.
Comments
Want to join the conversation?
Loading comments...